SynthesisAsian Pacific journal of cancer prevention : APJCP2026
Pertuzumab and Pathological Complete Response in Early HER2+ Breast Cancer: A Systematic Review and Meta-analysis of Real-World Studies.
Synthesis in Asian Pacific journal of cancer prevention : APJCP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHuman epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC) is an aggressive subtype that is associated with poorer outcomes. Neoadjuvant chemotherapy combined with trastuzumab has significantly improved prognosis, and the addition of pertuzumab has further enhanced the treatment response. Pathological complete response (pCR) is a reliable surrogate marker of long-term outcomes, and its achievement can inform surgical and adjuvant therapy decisions. While randomized controlled trials (RCTs) have demonstrated the benefits of dual HER2 blockade, real-world evidence (RWE) is critical for assessing treatment effectiveness in broader, more diverse populations.
objectiveTo evaluate the impact of dual HER2 blockade with pertuzumab and trastuzumab compared to single-agent trastuzumab on pCR rates in early-stage HER2+ breast cancer using real-world data.
methodsA systematic review and meta-analysis were conducted using the PubMed, Embase, and Scopus databases from inception to February 28, 2025. Eligible studies were retrospective or prospective real-world investigations comparing neoadjuvant chemotherapy with trastuzumab alone versus trastuzumab plus pertuzumab. Data were extracted independently by two reviewers. Pooled odds ratios (ORs) for pCR, along with 95% confidence intervals (CIs), were calculated. The risk of bias was assessed using the Newcastle-Ottawa Scale.
resultsEighteen studies involving 8,651 patients met the inclusion criteria. The pooled odds ratio (OR) showed significantly higher pCR rates with dual HER2 blockade (OR: 1.81; 95% CI: 1.56-2.09), with no observed heterogeneity (I² = 0%). Subgroup analyses confirmed consistent findings across geographic regions and study characteristics. Publication bias was low, as supported by Egger's test (p = 0.37).
conclusionIn real-world settings, adding pertuzumab to neoadjuvant therapy significantly improves pCR rates in early-stage HER2+ breast cancer, aligning with RCT evidence. These findings support the broader adoption of dual HER2 blockade and highlight the need for further prospective real-world studies to refine treatment strategies for specific patient subgroups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.